Premier Path Wealth Partners LLC Raises Position in GSK plc (NYSE:GSK)

Premier Path Wealth Partners LLC lifted its position in GSK plc (NYSE:GSK) by 21.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,274 shares of the pharmaceutical company’s stock after purchasing an additional 5,967 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in GSK were worth $1,159,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Cypress Wealth Services LLC grew its position in shares of GSK by 23.8% during the 4th quarter. Cypress Wealth Services LLC now owns 11,966 shares of the pharmaceutical company’s stock valued at $405,000 after acquiring an additional 2,301 shares during the period. Advisors Management Group Inc. ADV raised its position in shares of GSK by 6.1% during the 4th quarter. Advisors Management Group Inc. ADV now owns 91,530 shares of the pharmaceutical company’s stock worth $3,096,000 after purchasing an additional 5,259 shares during the last quarter. San Luis Wealth Advisors LLC lifted its stake in GSK by 37.8% in the 4th quarter. San Luis Wealth Advisors LLC now owns 21,968 shares of the pharmaceutical company’s stock valued at $743,000 after buying an additional 6,031 shares in the last quarter. Ignite Planners LLC raised its holdings in shares of GSK by 6.8% during the fourth quarter. Ignite Planners LLC now owns 18,965 shares of the pharmaceutical company’s stock valued at $635,000 after acquiring an additional 1,210 shares during the last quarter. Finally, Marcum Wealth LLC lifted its position in shares of GSK by 6.7% in the fourth quarter. Marcum Wealth LLC now owns 9,366 shares of the pharmaceutical company’s stock valued at $317,000 after acquiring an additional 591 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK opened at $33.46 on Friday. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a market capitalization of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. The company’s 50 day simple moving average is $34.08 and its 200 day simple moving average is $38.01. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.70%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s payout ratio is currently 96.10%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Monday, January 13th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.